In 3Q16, $COO reported cash from operations of $128.9MM. CapEx was $31.1MM, resulting in free cash flow of $97.8MM. Total debt increased slightly in the quarter to $1.4Bil, primarily due to higher average cash balances and acquisitions.
$STBA's BoD declared a quarterly cash dividend of $0.20 per share. This is an increase of 5.3% compared to dividend of $0.19 per share declared in the same period in the prior year. The annualized yield using the Jan. 23, 2017 closing price of $37.12 is $2.2%. The dividend is payable on Feb. 23, 2017 to shareholders of record on Feb. 9, 2017.
In pharma business, $JNJ expects to file 10 new products by 2019, each with at least $1Bil of potential sales. The company plans to file an additional 40 line extensions by 2019, 10 of which have more than $500MM in potential sales. In the medical devices business, $JNJ aims to return to above market growth by 2H17.
$MMM stated that regarding the underlying price growth in the US, the company's fundamental pricing power is not changing and is strong. Additionally, in the US, the company added that it took some targeted actions to help drive organic volume growth.
$VZ said that total revenue for 2017 would include the revenue of AOL, XO Communications, and possibly $YHOO if the transaction is closed. The company said IoT business will also see growth due to the Fleetmatics and Telogis acquisitions.
$BBOX said Anthony Massetti has decided to resign from his position as SVP, CFO and Treasurer. Massetti will remain in his current positions during a transition period and the company has engaged a national search firm to identify his successor.